Contract gene editing that adds drought tolerance to seed firms' own best lines
TL;DR Stomawise is a contract lab. It makes small, targeted edits for drought tolerance in the elite rice and millet lines that mid-size Indian seed companies already sell, then hands back edited seed for their own trials and launch. The seed company pays per project plus a royalty, and keeps its brand and dealers.
Dry spells hit Indian yields hard and unevenly. In Prakasam district of Andhra Pradesh, a field study found drought cut yields by 6.1% to 34.5%, with the worst losses on light, sandy soils[1]. A 2026 global analysis named South Asia as one of the hotspots for drought-driven crop losses, and found that rainfed production suffers more than irrigated[2].
Breeding tolerance the conventional way takes a decade per variety. Large multinationals and ICAR can run editing programmes, but what about everyone else? A seed company with ₹100–500 Cr in sales (our estimate of the target band) usually cannot hire a full editing team, so its best hybrids stay exposed.
What it does, in regulatory terms: plant breeding service using SDN-1 or SDN-2 edits that leave no foreign DNA. India treats such plants case by case and does not regulate them as GMOs when no foreign DNA remains[3]. Variety release, seed certification and plant variety protection rules still apply.
Here's how it works. A seed company sends seed of two or three of its best lines, and Stomawise edits genes that public research has already linked to water use, such as those that set leaf pore density. It removes the editing machinery in later generations and confirms by sequencing that no foreign DNA is left. The client gets edited, verified seed plus a data pack for its own multi-location trials.
We reframed the seed, which pitched a full platform that would also run agronomy. Owning varieties means years of trials and a dealer network. Selling edits into lines that already have buyers is the shorter path, and the edited line is probably an essentially derived variety of the client's own[4], which keeps ownership simple.
The user and payer are the same person - the head of breeding at a mid-size Indian seed company. A likely structure is a fee per line edited plus a small royalty per kilo of seed sold, though no public price exists for contract editing in India. State seed corporations and FPO-owned seed businesses are a second, slower buyer.
The policy door opened in India's favour. Two genome-edited rice varieties from ICAR's institute work have been approved, one for drought and salt tolerance and one for yield[3]. Abroad, gene-editing startups now license traits to other firms across many crops[5], which shows the contract model works.
There's no public figure for India's demand for contract gene editing. The narrowest signal is the approval of the two edited rice lines[3] and the drought losses above[1]. Treat the wider seed market as adjacent context, and I didn't find a reliable figure for it this time anyway.
ICAR institutes edit their own public varieties but don't work for private seed firms on contract. One US gene-editing startup proves a trait in one crop and then licenses it[5]. Another offers edited designs for elite germplasm to seed partners[6]. We could not verify an Indian private lab offering editing as a service, so the gap looks open, but check for in-house programmes at the larger Indian seed firms.
| Difficulty | Hard (66/100) |
| Starting capital | ₹6–11 Cr |
| Time to launch | 24–36 months |
The science is published, but regenerating edited plants from tissue culture is slow and crop-specific. Each line needs several generations to remove the editing cassette and confirm it is gone. Rights to the editing tools themselves need legal work. Field proof takes at least two seasons in several locations, and the monsoon won't hurry up for your investors.
Yes. Edited plants get a case-by-case review, and variety rules apply on top.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Don't let AI decide that a line is free of foreign DNA. Sequencing proves that, and a regulator reviews it.
Want to work out the AI layer for Stomawise? Talk to Yash →
Here's what can go south -
I think this suits a founder team with plant tissue-culture and molecular breeding experience, and patient capital. If you're expecting revenue inside two years then walk away. Prove first that three seed companies will co-fund a paid pilot on one crop, and that edited lines hold yield under managed drought in one season.
Plan for roughly ₹6–11 Cr for a molecular lab, tissue culture, sequencing and multi-season trials.
SDN-1 and SDN-2 edits with no foreign DNA are not regulated as GMOs, but you must prove the cassette is gone, and variety protection and seed rules still apply.
Yes, but rules on edited crops vary widely between countries. Check how your local regulator treats edits without foreign DNA before you plan trials.
The free Stomawise validation kit has the line-by-line capital breakdown, the effort scoring, the biosafety and variety-protection checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for seed company breeders, and 5 assumptions to test. Download the kit →
Thinking about building Stomawise or something close to it? The make-or-break work is getting edited lines through tissue culture and into two seasons of field proof that a seed firm trusts, and that's the kind of plan I help founders build. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.